Form 8-K - Current report:
SEC Accession No. 0001493152-24-045123
Filing Date
2024-11-13
Accepted
2024-11-13 16:05:24
Documents
15
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41330
2 ex99-1.htm EX-99.1 170154
3 ex99-1_001.jpg GRAPHIC 2370
  Complete submission text file 0001493152-24-045123.txt   412347

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE prph-20241113.xsd EX-101.SCH 3027
5 XBRL LABEL FILE prph-20241113_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE prph-20241113_pre.xml EX-101.PRE 24173
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3799
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 241454039
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)